Drugs · acquisition-cost intelligence
KOURZEQ
Triamcinolone Acetonide· ingredient triamcinoloneCorticosteroids· TRIAMCINOLONE ACETONIDE 1 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$2.80
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other triamcinolone products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| triamcinolone acetonide | $0.07238 | −$2.73 |
| Dermavyx | $0.08272 | −$2.72 |
| Triasil | $0.11513 | −$2.68 |
| Triamcinolone Acetonide | $0.18453 | −$2.62 |
| NYSTATIN AND TRIAMCINOLONE ACETONIDE | $0.23054 | −$2.57 |
| triamcinolone acetonide | $0.27895 | −$2.52 |
| nystatin and triamcinolone acetonide | $0.28013 | −$2.52 |
| TRIAMCINOLONE ACETONIDE | $0.31654 | −$2.48 |
Medicare Part D coverage · CY2026
On 327 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.